

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.
You can purchase shares of Upstream Bio (NASDAQ:UPB) through any online brokerage.
Other companies in Upstream Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Upstream Bio has a consensus price target of $33.57.
The stock price for Upstream Bio (NASDAQ: UPB) is $3.38 last updated November 10, 2026 at 4:00 PM EST.
There are no upcoming dividends for Upstream Bio.
Upstream Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Upstream Bio.
Upstream Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that...